Background: Human mutations in the gonadotropinreleasing hormone receptor (GnRHR) gene cause normosmic idiopathic hypogonadotropic hypogonadism (IHH). At least 19 different mutations have been identified in this G-protein-coupled receptor, which consist mostly of missense mutations. Objectives: To identify and determine the frequency of mutations in the coding region of the gonadotropinreleasing hormone receptor (GnRHR) gene in forty Chinese patients with normosmic idiopathic hypogonadotropic hypogonadism (IHH) and establish genotype/phenotype correlations where possible. Methods: The diagnosis of HH was based on absent or incomplete sexual development after 17 years of age in girls and 18 years in boys associated with low or normal levels of LH in both sexes and low levels of testosterone in males and of estradiol in females. All patients presented with a normal sense of smell in an olfactory specific test. Forty IHH patients and 40 controls were screened for mutations in the coding sequence of the GnRHR gene. The coding region of the GnRHR gene was amplified by PCR and directly sequenced. Results: A missense mutation, serine 168 arginine (S168R), located in the fourth transmembrane domain of the GnRHR gene, was identified as being in a homozygous state in one male with complete HH. The S168R mutation has been previously shown to be a cause in the complete loss of receptor function because hormone binding to the receptor is completely impaired. In another patient, a compound heterozygous mutation (Gln106Arg and Arg262Gln) was identified in a male with partial HH. The Gln106Arg mutation is located in the first extracellular loop of GnRH-R, this mutation decreases but not does eliminate GnRH binding; while Arg262Gln mutation is located in the third extracellular loop of GnRH-R and only decreases signal transduction. A good correlation between genotype and phenotype was found in our patients. The patient, who was homozygous for the completely inactivating S168R mutation, had
Introduction
The hypothalamic-pituitary-gonadal (HPG) axis sub serves a critical function in permitting sexual reproduction, both through the regulation of gametogenesis and the secretion of sex hormones, which confer secondary sexual characteristics (1) . Idiopathic hypogonadotropic hypogonadism (IHH) is characterized by delayed or absent sexual development associated with low levels of sex steroids in the presence of low or inappropriately normal LH and FSH in the absence of anatomical or functional abnormalities of the hypothalamic-pituitary-gonadal axis (2) . IHH is a heterogeneous condition, both clinically and genetically, that can be sporadic or familial cases inherited as either an X-linked or autosomal trait (3) .
IHH is characterized by a functional deficit in hypothalamic gonadotropin releasing hormone (GnRH) production or action (4, 5) . Patients with IHH have been classically divided into those with anosmia or hyposmia (Kallmann syndrome) and those with normal olfaction (6, 7) .
Congenital hypogonadotropic hypogonadism (CHH) affects mostly men and is rarely diagnosed before the onset of puberty unless it is associated with other signs or symptoms (anosmia or hyposmia, midline defect, cryptorchidism, color blindness, adrenal insufficiency) or when it is familial (8) .
Forty percent of autosomal recessive IHH cases and 16% of sporadic IHH cases are due to mutations in the GnRH receptor gene (9) . The phenotype of these patients seems to vary from partial hypogonadotropic deficiency, with significant levels of gonadotropins (LH, FSH) and gonadal steroids (10) , to complete hypogonadism (11) . A functional receptor for GnRH (GnRH-R) is also crucial to both normal pubertal development and reproductive function. To elicit the cascade of events leading to sex steroid hormone biosynthesis and secretion as well as gametogenesis, hypothalamic GnRH secreted into the hypophysial portal blood has to interact with its high affinity GnRH-R expressed in the membranes of pituitary gonadotrope cells (12) , ligand binding activates phospholipase C, increasing inositol triphosphate (IP3) and resulting in mobilization of intracellular calcium, with release of LH and FSH (13) .
The GnRHR gene is localized on human chromosome 4 (4q13.1) (14) and comprises three exons (15) and encodes a heptahelical transmembrane domain G protein-coupled receptor, lacking an intracellular carboxyl terminus normally seen in other members of this family (16, 17) . Exon 1 encodes the receptor amino terminus, transmembrane domains 1, 2, and 3, and part of transmembrane domain 4; the rest of the fourth and the fifth transmembrane domains and part of the third intracellular loop are encoded by exon 2, the remainder of the receptor being encoded by exon 3 (15, 18) .
Human mutations in the GnRHR gene cause autosomal recessive, normosmic idiopathic hypogonadotropic hypogonadism (IHH). At least 19 different mutations have been identified in this G-protein-coupled receptor, which consist mostly of missense mutations (6, 9, 10, 19 -27) . Most affected patients have compound heterozygous GnRHR mutations that may cause either complete IHH (no evidence of puberty) or incomplete IHH (partial evidence of puberty), although some genotypes are associated with mild disease in some families and severe disease in others. GnRHR mutations also appear to cause constitutional delay of puberty and one genotype (homozygosity for Gln106Arg) may be reversible in patients with IHH (28) . The mechanisms responsible for the loss of function of mutant GnRHR are currently under investigation. Defects may occur in the synthesis of receptors, in trafficking to the cell membrane and/or in internalization, recycling, or degradation of receptors, in legend binding, and/or in G protein coupling and signal transduction (6, 21) .
The purpose of this study was to investigate the presence of mutations in the coding region of the GnRHR gene in 40 Chinese patients with partial or complete HH with normal olfaction and establish genotype/phenotype correlations where possible. These studies demonstrate that GnRHR mutations can cause a broad range of reproductive phenotypes. GnRHR mutations, which appear to be distributed throughout the receptor, account for a larger proportion of both familial and sporadic cases of IHH than previously appreciated.
Subjects and methods

Subjects
The study was approved by the Ethical Committee of Tongji Hospital, Huazhong University of Science and Technology, Wuhan. Written consent was obtained from all patients. All patients had a Chinese ethnic origin. Thirty-fi ve hypogonadal male and fi ve hypogonadal female patients from the outpatient clinic of the Department of Pediatrics of Tongji Hospital, China participated in this study. The patients were sporadic cases. The diagnosis of IHH was based on the absence of spontaneous puberty by age 17 years in girls and 18 years in boys and hypogonadal sex steroid levels (testosterone, < 3.5 nmol/L; estradiol, < 73 pmol/L), in the setting of inappropriately normal or low gonadotropin levels upon repeated determinations.
Patients with genomic GnRHR mutations present with a wide spectrum of clinical symptoms, refl ecting the variable phenotypic expression of disease and the age at diagnostic evaluation. Clinical features in male patients include micro phallus, reduced testicular volumes, lack of virilization, reduced sexual function, and gynecomastia was noted in ∼ 20 % of male patients. Four patients had bilateral and two patients monolateral undescended testes. Females typically present with incomplete or absent pubertal development, including incomplete thelarche and primary amenorrhoea. The uterus is pre-pubertal sized and ovaries are small by ultrasound study. Complete IHH was defi ned as absent breast development in females and testicular size ≤ 3 mL in males (4 girls and 23 boys). Incomplete IHH suggested the presence of prior steroid production and was defi ned as breast development of Tanner ≥ 2 in females and testis size > 3 mL in males (1 girl and 12 boys). Additional elements for the diagnosis of IHH were: no evidence of a hypothalamic-pituitary anatomical lesion on imaging, and otherwise normal pituitary function as documented by normal basal and stimulated levels of prolactin, thyroid-stimulating hormone, growth hormone and cortisol. All patients were normosmic, as assessed by a smell test in which the patient was asked to identify odors produced by aromatic essences.
All the siblings had a normal karyotype. The GnRH stimulation test (100 μ g, IV) was performed in all patients. Serum LH and FSH levels were measured at -15, 0, 15, 30, 45, and 60 min aft er GnRH injection. Patients were categorized as having adult-onset IHH if they had undergone age-appropriate spontaneous sexual maturation by history (with proven paternity in some cases), but subsequently developed isolated IHH without an identifi able cause (29) . Zero patients had adult-onset IHH. The control group consisted of 45 eugonadal men and women from China with normal hormone levels and normal semen analysis.
Genomic DNA isolation, polymerase chain reaction and DNA sequencing DNA from 40 IHH patients was extracted from whole blood or lymphoblastoid cell lines using standard methodology (26) . The sequence for GnRHR gene was obtained from GenBank or the Human Genome database, PCR conditions were optimized to ensure that successful amplifi cation would not be a limiting factor in the experiments. Three sets of primers were used to amplify exon 1, two primer pair was used to amplify exon 2 and two primer pairs were used to amplify exon 3. The primers used are shown in Table 1 .
Reactions were performed in a fi nal volume of 50 μ L containing (50 nanograms) genomic DNA, 15 pmol of each PCR primer, 200 mmol of each deoxy-NTP and 2.5 U Taq polymerase (Invitrogen). PCR reactions were carried out for 35 cycles: denaturing at 94 ° C for 30 s, annealing at 55 -62 ° C for 30 s, elongation at 72 ° C for 1 min and a fi nal extension for 5 min at 72 ° C aft er the last cycle. The quality and predicted molecular size of each PCR product were assessed by electrophoresis through a 1 % agarose gel and sequenced by automatic DNA sequencing. For all exons, both strands were sequenced and compared. The mutation was confi rmed in three independent PCR amplifi cation sequences in all individuals studied.
Hormone measurements
Serum LH, FSH, estradiol and sex hormone were assayed by solid phase chemiluminescent immunometric assay (30) . In brief, the principle of the test is based on a solid phase enzyme-linked immunosorbent assay. The assay system utilizes one anti LH or anti FSH antibody for solid phase (microtiter wells) immobilization and another mouse monoclonal anti-antibody in the antibody-enzyme (horseradish peroxidase) conjugate solution. The test sample is allowed to react simultaneously with the antibodies, resulting in the molecules being sandwiched between the solid phase and enzyme-linked antibodies. After incubation for 60 min at room temperature, the wells are washed with water to remove unbound labeled antibodies. A solution of chemiluminescent substrate is then added and read relative light units (RLU) in an illuminometer. The intensity of the emitting light is proportional to the amount of enzyme present and is directly related to the amount of LH in the sample. By reference to a series of LH standards assayed in the same way, the concentration of LH in the unknown sample is quantified (31 -34) . The minimal detectable concentration of human LH and FSH by this assay is estimated to be 2 mIU/mL and 2.5 mIU/mL respectively. Both hormones are expressed IU/L as equivalents of the Second International Reference Preparation of the human menopausal gonadotropin (World Health Organization, 71/223). 
Primer
Clinical phenotype
Both probands were referred to the hospital because of hypogonadism. They were products of uneventful pregnancies.
Patient I was born with bilateral cryptorchidism, which was surgically corrected in early childhood. Psychomotor development in both patients was considered normal. On physical examination the most relevant findings were the following. Patient I, a 19-year-old man presented with features of severe HH, including a puerile voice, absence of pubic and axillary hair, micro phallus (15 mm extended length), hypo plastic scrotum, and testicular volume < 1 mL each. Moderate bilateral gynecomastia was detectable. His height was 171 cm, and his weight was 74 kg. The bone age, as radiologically determined, was retarded (15.0 years). Patient II was an 18-year-old man, height 163 cm and weight 56 kg. He reported impaired libido and physical examination revealed the absence of facial hair, sparse pubic hair (Tanner stage II), and a penis of 4 cm. He had scrotal testes and the volume of each was 4 mL. There was no gynecomastia. Both patients had a normal sense of smell and no mirror movements of the upper limbs, no abnormal eye movements, no color blindness, and no renal or craniofacial abnormalities. Both patients had 46, XY karyotype. Serum testosterone concentrations were in the prepubertal range (0.90 and 1. A big difference has been found in the level of testosterone and the basal and stimulated levels of LH and FSH between the two patients with extremely low levels in Patient I and almost no increase in stimulated LH level. 
Molecular studies
Direct sequencing of the three exons of the GnRHR gene revealed three mutations in two male patients; both patients exhibited a previously identified missense mutation (Table 2 , Figure 1 ). In Patient I with complete HH, in the first exon we identified a substitution of thymine, for adenine at nucleotide 504 of the GnRHR gene was present in the homozygote state in the proband. This single base substitution results in the mutation of serine 168 into arginine (S168R) in the fourth transmembrane domain of the GnRHR (Figure 2 A) . Two heterozygous mutations were found in Patient II with partial HH. In the first exon, a substitution of guanine for adenine at nucleotide 317 changed glutamine (Gln) into an arginine (Arg) at position 106, resulting in (Gln106Arg) a mutation in the first extracellular loop of the receptor ( Figure 2B ). In the third exon, the substitution of an adenine for a guanine at nucleotide 785 resulted in the replacement of arginine by glutamine at peptide position 262, resulting in an (Arg 262 Gln) mutation in the third intracellular loop ( Figure 2C ). The heterozygous state of each parent was confirmed by the presence of only one mutation (R262Q for the father, Gln106Arg for the mother) and the disorder was thus transmitted as an autosomal recessive trait. Parents of Patient I did not agree to participate in the study. Forty-five normal individuals (90 alleles) with proven fertility did not harbor the described mutations and homozygous wild type.
To elucidate the functional effect resulting from the mutation S168R, Pralong et al. 1999 (23) constructed a receptor mutant carrying the same mutation and compared its functional properties with those of the wild-type GnRHR. The ability of the mutant GnRHR to activate an intracellular signal transduction pathway was assessed by measuring inisitol triphosphate accumulation, an indicator of phospholipase C activity. Stimulation of cells expressing the wild-type GnRHR with a saturating concentration of GnRH resulted in a 25-fold increase in IP production. In contrast, cells transfected with the cDNA encoding the mutated GnRHR carrying the mutation S168R did not display any specific binding of GnRH or GnRHinduced accumulation of IP. These findings suggest that the mutation S168R results in the complete loss of receptor function, probably because hormone binding to the receptor is impaired. Alternatively, the mutation S168R might impair the expression of the receptor mutant in the cell membrane, resulting in both undetectable ligand binding Table 2 All (n = 19) different human GNRHR mutant alleles reported to date, including mutation location in the gene and protein, the number of times the allele has been reported, and the effects upon binding and IP3 signaling.
and complete loss of receptor function, thus the affected patient will suffer from severe features of hypogonadism. The Gln106Arg and Arg262Gln mutated receptors have been expressed and characterized previously by de Roux et al. 1997 (10) and the former mutation impairs hormone binding. In vitro analysis indicated that the mutant receptor was able to bind to GnRH, but with a reduced affinity, whereas an R262Q mutation in the third intracellular loop has been repeatedly described in IHH patients and in vitro studies, resulting in only partial impairment of signal transduction with decreased activation of phospholipase C without modifying ligand binding (24, 25) . With both mutated receptors, activation of phospholipase C was markedly diminished, although it was not completely suppressed, this was obvious in the phenotype and hormone levels of patient II, who suffers of partial form of hypogonadism.
Discussion
The pathogenesis of IHH has not yet been clarified in all cases. GnRH and its receptor are crucial for pubertal development, sexual maturation and reproductive competence. Point mutations in the GnRH-R gene are a recently identified cause of congenital isolated HH (6, 9, 10, 19 -27, 35 -37) . The phenotypic spectrum of HH patients with GnRHR gene mutations varies from partial to complete forms.
We report here a missense mutation at codon 168 of the GnRHR in the homozygous state in a male patient with HH. This patient has a complete form of HH as evidenced by bilateral cryptorchidism and undetectable levels of gonadotropins in the face of low testosterone values. The absence of an LH and FSH response after GnRH stimulation at 19 years of age confirmed the clinical features of complete hypogonadism.
The integrity of serine 168 in the fourth transmembrane domain is crucial for receptor function. The importance of this region of the GnRHR was demonstrated when the S168R mutation was introduced in the wildtype GnRHR; it resulted in a receptor mutant that totally failed to mediate the GnRH-induced stimulation of inositol phosphate production (23) . Consistent with this report, the S168R mutation resulted in complete elimination of detectable ligand binding and complete loss of the ability to activate intracellular signal transduction pathway.
In addition, the GnRHR mutant carrying the mutation of S168R was impaired in its ability to bind GnRH (23) . Alternatively, the mutation of serine 168 into arginine has a disruptive effect on the receptor conformation, resulting in both undetectable ligand binding and the complete loss of receptor function. These results demonstrate a relationship between the mutation of serine 168 into arginine and the severity of the clinical phenotype observed. The S168R was also described by Pralong et al. 1999 (23) in a homozygous state in a 19-year-old male patient who displayed a conserved sense of smell, eunuchoid habitus, no facial or thoracic hair, bilateral cryptorchidism (complete HH), and undetectable levels of gonadotropins in the face of low testosterone levels associated with resistance to exogenous GnRH stimulation. The clinical presentation and the hormonal results of the patient described by Pralong 
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Wild type mutant et al. and Patient I in this study demonstrate that the S168R mutation results in severe HH when present alone in the homozygous state. We also describe two other mutations (Gln106Arg and Arg262Gln) in the GnRHR in a male patient with HH. The affected member was compound heterozygote for these mutations. The disease is transmitted as an autosomal recessive trait. The male propositus presented with a typical case of incomplete idiopathic HH, he had Tanner stage II pubic hair, 4 mL-sized testes and the results of the GnRH stimulation test were near normal, probably because the high dose of GnRH overcame the partial receptor defect. The clinical and hormonal findings of this patient indicate partial hypogonadism and suggest that the compound heterozygous mutations (Gln106Arg and Arg262Gln) did not completely inactivate GnRHR function.
The Gln106Arg mutation in the first extracellular loop of the GnRHR is one of the most frequent mutations found in this receptor in patients with congenital isolated HH ( Table 2 ). Functional studies of the Gln106Arg receptor mutant with experimentally produced mutations in the same region (Asn102Ala) results in almost complete abolition of GnRH binding in association with reduced activation of intracellular signaling pathways in response to GnRH (10) . Gln106Arg receptor was able to bind to GnRH, but with low affinity, therefore Gln106Arg mutants may be capable of transmitting GnRH signal but in a reduced fashion.
The second mutation in the patient (Arg262Gln) affected a residue located in the third intracellular loop.
In vitro expression studies showed that this mutated receptor binds GnRH but a 10-to 50-fold increase in the amount of GnRH agonist is needed to induce a 50 % maximal increase in IP3 production.
Site-directed mutagenesis of the GnRHR has also shown that the Ala residue at position 261, near R262, does not affect ligand binding but is critical for binding of the receptor to the G protein (39) . Therefore hormone binding was unchanged, but signal transmission was impaired.
The partial impairment of the hormonal response of the mutant receptors is compatible with the incomplete phenotype in our patient. The Gln106Arg and Arg262Gln were previously described by de Roux et al. 1997 (10) , in a heterozygous state in a 22-year-old male patient who displayed sparse pubic hair (Tanner stage 3), penis length 6 cm, and scrotal testes of 8 mL volume, low testosterone levels, normal level of gonadotropin hormones, and the patient was suffering of incomplete HH.
We observed a good correlation between genotype and phenotype in our patients with GnRHR mutations. The first patient, who is homozygous for the completely inactivating S168R mutation, has complete HH with undetectable serum basal LH and FSH levels that failed to respond to GnRH stimulation. In the second patient, who is compound heterozygous for the Gln106Arg and Arg262Gln mutations, there were partial HH with low serum basal LH levels that were responsive to GnRH stimulation. There was no difference between the clinical and hormonal data of patients with and without mutations in the GnRHR gene, indicating that these data do not contribute to the identification of HH patients harboring GnRHR mutations. The relatively large number of patients now identified allows genotype-phenotype relationships to be established between the degree of GnRHR signal transduction inhibition and the partial or complete nature of CHH (6, 9, 10, 19 -27, 35 -37, 41 -45) (Figure 3 ). To date, several different mutations have been described in the GnRHR gene: a total of 19 different GnRHR mutant alleles, all confirmed by functional analyses, which have been described in IHH patients (Table 1, Figure 1 ). Of these confirmed mutant alleles, 17 were missense mutations, one was a non-sense mutation, and one was a splice site mutation (Table 1) . Of the confirmed mutations, ten were found in exon 1, two were identified in exon 2, and six were seen in exon 3. The splice mutant was identified at the splice donor site in intron 1, which resulted in exon skipping (6) .
Nevertheless, two mutations appear to be particularly common, even among different ethnic groups: Gln106Arg represents 13 of 48 (27.1 % ) mutant alleles and Arg262Gln constitutes 8 of 46 (17.4 % ) mutant alleles (Table 1) . These 19 mutations result in a broad phynotypic spectrum varying from mild forms, as in the fertile eunuch syndrome (40) , to complete GnRH resistance (19, 23) as shown in Figure 3 . An important finding of this study is that mutations that cause functional changes in the GnRHR can lead to strikingly different clinical phenotypes.
Although studying patients with identical GnRHR mutations is important, sometimes genotype/phenotype correlation is not easy to make. For example, Patient II in this study has the identical genotype (Gln106Arg, Arg262Gln) as Patient I reported with a GnRHR mutation by Beranova et al. (9) , a female who had absence of breast development, one non-estrogen-induced menstrual bleed, no gonadotropin responses to 100 μ g GnRH, iv, and erratic low amplitude LH pulsations, suggesting that the patient in this study had a less severe phenotype than the one described by Beranova although they have the same GnRHR mutations. Thus, identical GnRHR mutations do not lead to identical phenoypes.
Other reports in the literature describe different gender discrepancies. For example, two sisters with breast development had gonadotropin levels that responded to a single injection of GnRH, whereas their brother with complete IHH had no gonadotropin response (25) . Therefore, there may be sexually dimorphic responses to GnRHR mutations at both pituitary and gonadal levels. Such phenotypic differences may be due to a variety of factors. Several genes are probably involved in gonadotrope cell development, and functional allelic variation in such genes may affect GnRH action.
In summary, from a large, heterogeneous population of patients with IHH, we have described two men with IHH caused by loss of function mutation in the GnRHR gene. A good correlation between phenotype and genotype was observed in these two cases, one with complete IHH caused by a homozygous mutation, and the partial IHH patient caused by two heterozygous mutations. Mutations in the human GnRHR gene have contributed greatly to the understanding of normosmic IHH, as well as the structure and function of the GnRHR. Mutations of the GnRHR gene should be investigated for in patients with IHH, especially in familial cases and when an autosomal recessive mode of inheritance is suspected.
